© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters
aDepartment of Medical Technology, Nagoya University School of Health Sciences, 1-1-20 Daiko Minami, Higashi, Nagoya 461-8673, Japan
bCardiovascular Division, Department of Clinical Pathophysiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
cDepartment of Cardiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan
* Corresponding author. Tel./fax: +81-52-719-1546. iwase{at}met.nagoya-u.ac.jp
Objective: The mammalian heart contains specific growth hormone-releasing peptide (GHRP) binding sites whose physiological significance is unknown. We sought to compare the effects of GHRP and GH on progressive left ventricular (LV) dysfunction in the TO-2 hamster model of dilated cardiomyopathy. Methods: TO-2 hamsters (8 weeks old) were injected with GHRP-6 (100 µg/kg day), GH (2 mg/kg day), or saline for 4 weeks; F1B hamsters served as controls. LV functional and structural changes were evaluated by echocardiography and pathology. Results: The increase in body weight of GH-treated TO-2 hamsters was greater than that of animals in the other two groups. Plasma GH and insulin-like growth factor-1 (IGF-1) concentrations were not increased by GHRP-6. LV fractional shortening (LVFS) decreased from 42.0±2.6% to 25.4±1.8% and the LV end-diastolic dimension (LVDd) increased from 4.0±0.1 to 5.0±0.1 mm in untreated TO-2 hamsters between 8 and 12 weeks. LVFS was substantially improved by treatment with GHRP-6 (33.4±2.0%) or GH (32.0±2.1%). The LVDd was significantly smaller in animals treated with GHRP-6 than in those treated with GH. The cross-sectional LV myocyte area and the amount of atrial natriuretic peptide mRNA in the LV were increased by GH but not by GHRP-6. Treatment woth GH at a lower dose (0.2 mg/(kg day)) exerted minimal cardiac and systematic growth effects without improving LV function. Conclusion: GHRP can ameliorate the development of progressive LV dysfunction independently of the GH-IGF-1 axis, suggesting a potential new approach to the heart failure.
KEYWORDS Growth hormone-releasing peptide; Growth hormone; Cardiomyopathic hamsters; LV dysfunction
Time for primary review 23 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Xu, J. Pang, H. Yin, M. Li, W. Hao, C. Chen, and J.-M. Cao Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2952 - H2958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Baessler, M. Fischer, B. Mayer, M. Koehler, S. Wiedmann, K. Stark, A. Doering, J. Erdmann, G. Riegger, H. Schunkert, et al. Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease Hum. Mol. Genet., April 15, 2007; 16(8): 887 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marleau, M. Mulumba, D. Lamontagne, and H. Ong Cardiac and peripheral actions of growth hormone and its releasing peptides: Relevance for the treatment of cardiomyopathies Cardiovasc Res, January 1, 2006; 69(1): 26 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pecker Ghrelin in the heart and growth hormone: which is chicken, which is egg? Cardiovasc Res, June 1, 2004; 62(3): 442 - 443. [Full Text] [PDF]
|
|
|
|
|
|
P. A Lucchesi Growth hormone-releasing peptides and the heart: secretagogues or cardioprotectors? Cardiovasc Res, January 1, 2004; 61(1): 7 - 8. [Full Text] [PDF]
|
|